drug · protein
efineptakin alfa
Phase 2updated 5mo agoby NeoImmuneTech Inc🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Phase 2 (across all indications), with 5 investigational indications.
indications
indications
NSCLCColorectal Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying efineptakin alfa
- phase2Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- phase1Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- phase1NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
- phase2NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
News(2)
- Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drugAfter vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.fiercebiotech · 1d ago
- Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion proteinTolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.fiercebiotech · 1mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that